Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression

Molecular Therapy

Volumn 4, Issue 6, 2001, Pages 551-558

  Qin, Hongxing ^a   Valentino, Joseph ^b   Manna, Subha ^a   Tripathi, Pulak K ^a   Bhattacharya Chatterjee, Malaya ^a   Foon, Kenneth A ^a   O'Malley Jr , Bert W ^c   Chatterjee, Sunil K ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Head and neck squamous cell carcinoma; IL 2; Immune suppression; Tumor vaccine; Vaccinia virus

Indexed keywords

CANCER VACCINE; CONCANAVALIN A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2; NITRIC OXIDE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE THERAPY; HEAD CANCER; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE CELL; MOUSE; MOUTH CANCER; NECK CANCER; NONHUMAN; SPLEEN CELL; SQUAMOUS CELL CARCINOMA; TUMOR CELL CULTURE; TUMOR GROWTH; VACCINIA VIRUS; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANIMALIA; MURINAE; VACCINIA VIRUS;

EID: 0035665098     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0493     Document Type: Article

References (46)

1. The surgical pathology of head and neck cancer
2. Cancer statistics, 1994
3. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report
4. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases
5. Head and neck cancer
6. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2
7. Interleukins and contrasuppression; induce immune regression of head and neck cancer
8. Expansion of tumor-infiltrating lymphocytes from human solid tumors in interleukin-2
9. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck
10. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells
11. Interleukin 2 receptors on squamous cell carcinomas of the head and neck. Characterization and functional role
12. Antiproliferative effects of cytokines on squamous cell carcinoma
13. Tumor immunotherapy by local injection of interleukin 2 and non-reactive lymphocytes. Experimental and clinical results
14. Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma
15. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically
16. Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer
17. Murine interleukin-4 displays potent anti-tumor activity in vivo
18. Tumor-associated eosinophilia in interleukin-2-treated patients: Evidence of toxic eosinophil degranulation on bladder cancer cells
19. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo
20. An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts
21. Metastatic patterns in squamous cell cancer of the head and neck
22. Pharmacokinetics of recombinant interleukin 2 in humans
23. A biologic assay for IL-4. Rapid fluorescence assay for IL-4 detection in supernatants and serum
24. Vaccinia virus expression vectors
25. Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine
26. Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine
27. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF
28. Recombinant vaccinia expressing interleukin-2 for cancer gene therapy
29. A new immunocompetent murine model for oral cancer
30. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas
31. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression
32. Combination gene therapy for oral cancer in a murine model
33. Interactions between autologous CD4+ and CD8+ T lymphocytes and human squamous cell carcinoma of the head and neck
34. Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer
35. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-β and nitric oxide
36. Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes
37. Molecular basis of "suppressor" macrophages. Arginine metabolism via the nitric oxide synthetase pathway
38. Selective expression of interleukin 10, interferon γ, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies
39. Characterization of immunosuppressive functions of murine peritoneal macrophages induced with various agents
40. Tumor-induced immunosuppression: A barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine
41. Gene therapy using intratumoral (IT) recombinant GM-CSF encoding vaccinia virus in patients with melanoma
42. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
43. The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer
44. Distribution and modulation of the cellular receptor for transforming growth factor-β
45. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells
46. T cell growth factor: Parameters of production and a quantitative microassay for activity